金迪克 (688670)
Jiangsu gdk Biotechnology Co., Ltd.
K-Line Chart
No K-line data available
Company NameJiangsu Jindike Biotechnology Co., Ltd.
Listing Date2021-08-02
Issue Price55.18RMB
Registered Capital1232010k RMB
Legal RepresentativeYu Jun
Registered AddressNo. 12, Tulip Road, Taizhou City, Jiangsu Province
IndustryBiological Products
Main BusinessFocusing on the research and development, production, and sales of human vaccines.
Company ProfileJiangsu Jindike Biotechnology Co., Ltd. has successfully developed and commercialized its core product, the quadrivalent influenza split vaccine. It is the only quadrivalent influenza vaccine in China submitted to the Center for Drug Evaluation (CDE) as a Category 1 biological product for prevention. As an upgraded version of the traditional trivalent influenza vaccine, it outperforms the standards of the Chinese Pharmacopoeia in several key indicators, offering advantages of high immunogenicity and safety. In 2019, the company was one of only two domestic enterprises to achieve batch release and market sales of the quadrivalent influenza vaccine, with a batch release volume of 1.3496 million doses that year. As of September 30, 2020, the company has established a marketing network covering over 1,300 district and county-level Centers for Disease Control and Prevention (CDCs) across 27 provinces (municipalities and autonomous regions) nationwide, laying a solid foundation for its future brand development and market expansion of products under research.
Stock Details
1. Key Indicators
- Total Shares(W): 12320.00
- Circulating A-Shares(W): 12320.00
- Earnings Per Share(RMB): -0.7000
- Net Assets Per Share(RMB): 9.6681
- Operating Revenue(W RMB): 7465.76
- Total Profit(W RMB): -10916.75
- **Net Profit Attributable to Parent(W RMB) **: -8647.06
- Net Profit Growth Rate(%): -61.74
- Weighted Return on Equity(%): -7.0100
- Operating Cash Flow Per Share(RMB): -1.0640
- Undistributed Profit Per Share(RMB): -0.6066
- Capital Reserve Per Share(RMB): 9.0601
2. Main Business
The main business covers:
- Research, development, production, and sales of human vaccines
3. Company Basic Information
- Company Name: Jiangsu GDK Biotech Co., Ltd.
- Listing Date: 2021-08-02
- Industry: Pharmaceutical Manufacturing
- Address: No. 12 Yujin Road, Taizhou City, Jiangsu Province
- Website: https://www.gdkbio.com/
- Company Profile: On June 15, 2020, GDK Limited held a shareholders' meeting where all shareholders unanimously agreed to convert GDK Limited into a joint stock company as a whole, with the base date set as May 31, 2020. On the same day, the seven shareholders of GDK Limited signed the "Sponsor Agreement for the Joint Establishment of Jiangsu GDK Biotech Co., Ltd." On June 15, 2020, the issuer held its founding meeting. Based on the net assets of RMB 86.9303 million confirmed in the "Audit Report" (Dahua Audit No. [2020]0010873) issued by Dahua Certified Public Accountants as of May 31, 2020, the company was converted into a joint stock company as a whole at a ratio of 1.3171:1, resulting in 66 million shares. The balance of the net assets after deducting the share capital, RMB 20.9303 million, was recorded as capital reserve. On June 13, 2020, Guozhonglian Appraisal assessed the net assets of GDK Limited as of May 31, 2020 and issued the "Asset Appraisal Report on the Net Asset Value of Jiangsu GDK Biotech Co., Ltd. Involved in the Planned Joint-stock System Transformation", confirming that the book value of GDK Limited's net assets on the appraisal base date was RMB 86.9303 million, and the appraised net asset value was RMB 156.9592 million. On June 15, 2020, Dahua Certified Public Accountants issued the "Capital Verification Report" (Dahua Verification No. [2020]000241), verifying the capital for this overall conversion. On June 16, 2020, the company completed the industrial and commercial change and obtained the "Business License" issued by the Taizhou Administrative Approval Bureau. The company was established by sponsorship and registered with the Jiangsu Province Taizhou Administrative Approval Bureau, obtaining a business license. Unified Social Credit Code: 9132129168412218X6.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Taizhou Tongren Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 166.32 | 1.35 |
| 2 | Taizhou Tongze Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 166.32 | 1.35 |
5. Concept Sectors
- Biological Vaccines
- Margin Trading & Securities Lending
- Micro-Cap Stocks
- Consecutive Losses
- Recent Highs
- Broken Issue Price
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information